X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs FRESENIUS KABI ONCO. - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD FRESENIUS KABI ONCO. STRIDES SHASUN LTD/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 13.7 22.1 62.0% View Chart
P/BV x 1.6 3.1 51.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES SHASUN LTD   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
FRESENIUS KABI ONCO.
Mar-13
STRIDES SHASUN LTD/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,275176 724.3%   
Low Rs91879 1,169.4%   
Sales per share (Unadj.) Rs389.637.7 1,033.7%  
Earnings per share (Unadj.) Rs28.05.1 549.1%  
Cash flow per share (Unadj.) Rs48.96.7 727.3%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs303.142.5 712.5%  
Shares outstanding (eoy) m89.42158.23 56.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.4 83.3%   
Avg P/E ratio x39.225.0 156.9%  
P/CF ratio (eoy) x22.418.9 118.5%  
Price / Book Value ratio x3.63.0 120.9%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m98,03620,135 486.9%   
No. of employees `0005.81.2 503.5%   
Total wages/salary Rs m5,881703 836.3%   
Avg. sales/employee Rs Th6,005.95,176.2 116.0%   
Avg. wages/employee Rs Th1,014.0610.4 166.1%   
Avg. net profit/employee Rs Th431.2699.6 61.6%   
INCOME DATA
Net Sales Rs m34,8345,963 584.2%  
Other income Rs m1,68618 9,365.6%   
Total revenues Rs m36,5205,981 610.6%   
Gross profit Rs m6,4281,430 449.5%  
Depreciation Rs m1,872258 725.7%   
Interest Rs m2,269-26 -8,728.1%   
Profit before tax Rs m3,9731,216 326.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006-68 1,476.8%   
Tax Rs m470342 137.3%   
Profit after tax Rs m2,501806 310.3%  
Gross profit margin %18.524.0 76.9%  
Effective tax rate %11.828.1 42.0%   
Net profit margin %7.213.5 53.1%  
BALANCE SHEET DATA
Current assets Rs m38,1655,102 748.1%   
Current liabilities Rs m30,4022,385 1,274.5%   
Net working cap to sales %22.345.6 48.9%  
Current ratio x1.32.1 58.7%  
Inventory Days Days77150 51.5%  
Debtors Days Days104113 92.2%  
Net fixed assets Rs m37,6395,148 731.1%   
Share capital Rs m894158 565.2%   
"Free" reserves Rs m26,2106,556 399.8%   
Net worth Rs m27,1056,732 402.6%   
Long term debt Rs m16,377952 1,719.9%   
Total assets Rs m81,16810,388 781.4%  
Interest coverage x2.8-45.8 -6.0%   
Debt to equity ratio x0.60.1 427.2%  
Sales to assets ratio x0.40.6 74.8%   
Return on assets %5.97.5 78.3%  
Return on equity %9.212.0 77.1%  
Return on capital %12.114.6 82.5%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m13,4655,298 254.2%   
Fx outflow Rs m4,0761,772 230.0%   
Net fx Rs m9,3893,525 266.3%   
CASH FLOW
From Operations Rs m2,8811,274 226.2%  
From Investments Rs m-7,051-1,204 585.6%  
From Financial Activity Rs m3,382-196 -1,724.7%  
Net Cashflow Rs m-788-126 623.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 37.8 0.3 12,600.0%  
FIIs % 8.6 9.6 89.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 9.1 284.6%  
Shareholders   56,241 42,599 132.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  PLETHICO PHARMA  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS